These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23072897)

  • 1. The economic impact of gout: a systematic literature review.
    Trieste L; Palla I; Fusco F; Tani C; Baldini C; Mosca M; Turchetti G
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S145-8. PubMed ID: 23072897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
    Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
    Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of the Economic and Humanistic Burden of Gout.
    Shields GE; Beard SM
    Pharmacoeconomics; 2015 Oct; 33(10):1029-47. PubMed ID: 25969152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic burden of gout: A systematic review.
    Rai SK; Burns LC; De Vera MA; Haji A; Giustini D; Choi HK
    Semin Arthritis Rheum; 2015 Aug; 45(1):75-80. PubMed ID: 25912932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of health care costs and utilization patterns for patients with gout.
    Park H; Rascati KL; Prasla K; McBayne T
    Clin Ther; 2012 Mar; 34(3):640-52. PubMed ID: 22381710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic burden of uncontrolled gout: how controlling gout reduces cost.
    Flores NM; Nuevo J; Klein AB; Baumgartner S; Morlock R
    J Med Econ; 2019 Jan; 22(1):1-6. PubMed ID: 30289009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Direct Economic Burden of Gout in an Elderly Canadian Population.
    Fischer A; Cloutier M; Goodfield J; Borrelli R; Marvin D; Dziarmaga A
    J Rheumatol; 2017 Jan; 44(1):95-101. PubMed ID: 27803136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic burden of gout on an employed population.
    Brook RA; Kleinman NL; Patel PA; Melkonian AK; Brizee TJ; Smeeding JE; Joseph-Ridge N
    Curr Med Res Opin; 2006 Jul; 22(7):1381-9. PubMed ID: 16834837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis.
    Jackson R; Shiozawa A; Buysman EK; Altan A; Korrer S; Choi H
    BMJ Open; 2015 Jun; 5(6):e007214. PubMed ID: 26109113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of illness and determinants of costs among patients with gout.
    Spaetgens B; Wijnands JM; van Durme C; van der Linden S; Boonen A
    J Rheumatol; 2015 Feb; 42(2):335-44. PubMed ID: 25399391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis.
    Halpern R; Fuldeore MJ; Mody RR; Patel PA; Mikuls TR
    J Clin Rheumatol; 2009 Feb; 15(1):3-7. PubMed ID: 19125135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of 'state-of-the-art' cost-of-illness studies. Comment on: The economic burden of gout: A systematic review.
    Spaetgens B; Boonen A
    Semin Arthritis Rheum; 2016 Feb; 45(4):e9. PubMed ID: 26170227
    [No Abstract]   [Full Text] [Related]  

  • 15. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
    Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resource use and economic impact of patients with gout: a multicenter, population-wide study.
    Sicras-Mainar A; Navarro-Artieda R; Ibáñez-Nolla J
    Reumatol Clin; 2013; 9(2):94-100. PubMed ID: 23313534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
    Wu EQ; Patel PA; Mody RR; Yu AP; Cahill KE; Tang J; Krishnan E
    J Rheumatol; 2009 May; 36(5):1032-40. PubMed ID: 19369467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
    Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
    Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011.
    Rai SK; Aviña-Zubieta JA; McCormick N; De Vera MA; Lacaille D; Sayre EC; Choi HK
    Arthritis Care Res (Hoboken); 2017 May; 69(5):758-762. PubMed ID: 27565008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.
    Kesselheim AS; Franklin JM; Kim SC; Seeger JD; Solomon DH
    J Gen Intern Med; 2015 Nov; 30(11):1633-8. PubMed ID: 25855479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.